Anavex Life Sciences’ Blarcamesine Demonstrates Promising Results in Alzheimer’s Trial
Anavex Life Sciences has announced significant findings from its phase 2b/3 trial of blarcamesine, an
investigational treatment for early Alzheimer’s disease. The trial results
indicate that blarcamesine could play a crucial role in reducing amyloid-ß
biomarkers and slowing neurodegeneration.
Conducted across multiple centers, this double-blind, placebo-controlled study enrolled 508
participants. Patients were randomized to receive...